In this Review:
Alectinib vs crizotinib in ALK-positive NSCLC
First-line nivolumab + ipilimumab in advanced NSCLC
Nivolumab ± ipilimumab for recurrent SCLC
Single-agent tremelimumab: no benefit in malignant mesothelioma
Avelumab in advanced unresectable mesothelioma
Rovalpituzumab tesirine in recurrent or refractory SCLC
Lorlatinib in advanced ALK+ or ROS1+ NSCLC
Osimertinib shows promise in EGFR-mutant NSCLC
ctDNA successfully detects resistance mechanisms
Dabrafenib + trametinib in BRAFmutant NSCLC
Please login below to download this issue (PDF)